

Kenneth M Mcdonald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1442517/publications.pdf>

Version: 2024-02-01

55
papers

3,107
citations

331538

21
h-index

168321

53
g-index

55
all docs

55
docs citations

55
times ranked

4376
citing authors

#	ARTICLE	IF	CITATIONS
1	Natriuretic Peptide-Based Screening and Collaborative Care for Heart Failure. JAMA - Journal of the American Medical Association, 2013, 310, 66.	3.8	473
2	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 2019, 21, 715-731.	2.9	446
3	Diastolic Heart Failure. Circulation, 2007, 115, 888-895.	1.6	407
4	European Society of Cardiology Heart Failure Association Standards for delivering heart failure care. European Journal of Heart Failure, 2011, 13, 235-241.	2.9	197
5	Effects of Serelaxin in Patients with Acute Heart Failure. New England Journal of Medicine, 2019, 381, 716-726.	13.9	174
6	Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?. European Journal of Heart Failure, 2011, 13, 1087-1095.	2.9	168
7	Natural History of Markers of Collagen Turnover in Patients With Early Diastolic Dysfunction and Impact of Eplerenone. Journal of the American College of Cardiology, 2009, 54, 1674-1682.	1.2	116
8	Exaggerated Inflammation and Monocytosis Associate With Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction: Evidence of M2 Macrophage Activation in Disease Pathogenesis. Journal of Cardiac Failure, 2015, 21, 167-177.	0.7	108
9	Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. European Journal of Heart Failure, 2009, 11, 191-197.	2.9	107
10	Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care. EPMA Journal, 2019, 10, 445-464.	3.3	96
11	Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations. Journal of the American College of Cardiology, 2016, 68, 1420-1431.	1.2	85
12	Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (<scp>HFA</scp>), European Society of Cardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2021, 23, 1610-1632.	2.9	69
13	Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. European Journal of Heart Failure, 2008, 10, 267-272.	2.9	61
14	Targeted DNA Methylation Profiling of Human Cardiac Tissue Reveals Novel Epigenetic Traits and Gene Deregulation Across Different Heart Failure Patient Subtypes. Circulation: Heart Failure, 2019, 12, e005765.	1.6	58
15	Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure, 2015, 17, 672-679.	2.9	42
16	Long-Term Statin Therapy in Patients With Systolic Heart Failure and Normal Cholesterol: Effects on Elevated Serum Markers of Collagen Turnover, Inflammation, and B-Type Natriuretic Peptide. Clinical Therapeutics, 2012, 34, 91-100.	1.1	38
17	Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. European Journal of Heart Failure, 2004, 6, 235-243.	2.9	35
18	Nondipping Nocturnal Blood Pressure Predicts Sleep Apnea in Patients With Hypertension. Journal of Clinical Sleep Medicine, 2019, 15, 957-963.	1.4	31

#	ARTICLE	IF	CITATIONS
19	B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1553-1560.	2.9	29
20	Heart omics™ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. <i>Journal of Biomedical Research</i> , 2014, 28, 349.	0.7	24
21	Attenuation of Monocyte Chemotaxis: A Novel Anti-inflammatory Mechanism of Action for the Cardio-protective Hormone B-Type Natriuretic Peptide. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 545-557.	1.1	23
22	Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS). <i>Journal of Cardiac Failure</i> , 2019, 25, 654-665.	0.7	23
23	A systematic review of clinical prediction rules for the diagnosis of chronic heart failure. <i>ESC Heart Failure</i> , 2019, 6, 499-508.	1.4	20
24	Heart Failure Virtual Consultation: bridging the gap of heart failure care in the community – A mixed methods evaluation. <i>ESC Heart Failure</i> , 2017, 4, 252-258.	1.4	19
25	Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study. <i>European Journal of Heart Failure</i> , 2018, 20, 474-480.	2.9	19
26	Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study. <i>European Journal of Heart Failure</i> , 2020, 22, 251-263.	2.9	19
27	Life expectancy for community-based patients with heart failure from time of diagnosis. <i>International Journal of Cardiology</i> , 2015, 178, 268-274.	0.8	17
28	FKBP1 is associated with metabolic parameters and is a novel determinant of cardiovascular disease. <i>Scientific Reports</i> , 2020, 10, 21655.	1.6	17
29	Tetanectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis. <i>Scientific Reports</i> , 2020, 10, 7507.	1.6	17
30	Screening to prevent heart failure (STOP-HF): expanding the focus beyond asymptomatic left ventricular systolic dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 480-486.	2.9	15
31	Changing to remote management of a community heart failure population during COVID-19 – Clinician and patient perspectives™. <i>IJC Heart and Vasculature</i> , 2020, 31, 100665.	0.6	14
32	Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 1122-1130.	2.9	14
33	Natriuretic Peptide-based Screening and Prevention of Heart Failure. <i>Cardiac Failure Review</i> , 2017, 3, 83.	1.2	14
34	Progression of left atrial volume index in a population at risk for heart failure: a substudy of the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) trial. <i>European Journal of Heart Failure</i> , 2012, 14, 957-964.	2.9	13
35	Improvement but no cure of left ventricular systolic dysfunction in treated heart failure patients. <i>European Journal of Heart Failure</i> , 2007, 9, 1196-1204.	2.9	12
36	B-Type Natriuretic Peptide and Ventricular Dysfunction in the Prediction of Cardiovascular Events and Death in Hypertension. <i>American Journal of Hypertension</i> , 2018, 31, 228-234.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 533-541.	0.7	11
38	Screening for Asymptomatic Left Ventricular Dysfunction Using B-type Natriuretic Peptide. <i>Congestive Heart Failure</i> , 2008, 14, 5-8.	2.0	10
39	B-type natriuretic peptide measurement in primary care; magnitude of associations with cardiovascular risk factors and their therapies. Observations from the STOP-HF (St. Vincent's) Trial. <i>Journal of Cardiac Failure</i> , 2011, 17, 1076-1084.	1.0	7
40	Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure. <i>American Journal of Cardiology</i> , 2021, 147, 70-79.	0.7	7
41	Decongestion, kidney injury and prognosis in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2022, 354, 29-37.	0.8	6
42	Anemia in heart failure: To treat or not to treat?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 455-464.	0.4	5
43	The prehospital patient pathway and experience of care with acute heart failure: a comparison of two health care systems. <i>ESC Heart Failure</i> , 2021, 8, 1076-1084.	1.4	5
44	The practice gap in heart failure—the elephant in the room. <i>European Journal of Heart Failure</i> , 2017, 19, 301-303.	2.9	4
45	Developing a disease management program for the improvement of heart failure outcomes: the do and don'ts. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 267-273.	0.6	4
46	Need and evolution of need for device therapy in a community heart failure population. <i>European Journal of Heart Failure</i> , 2008, 10, 601-607.	2.9	3
47	Role of Monitoring Devices in Preventing Heart Failure Admissions. <i>Current Heart Failure Reports</i> , 2015, 12, 269-275.	1.3	3
48	Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?. <i>International Journal of Heart Failure</i> , 2021, 3, 106.	0.9	3
49	A survey-based triage tool to identify patients potentially eligible for referral to an advanced heart failure centre. <i>ESC Heart Failure</i> , 2022, 9, 3643-3648.	1.4	3
50	New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 378-380.	2.9	2
51	Heart failure: An ongoing survey of management practice and patient understanding in a regional teaching hospital. <i>Journal of Cardiac Failure</i> , 1998, 4, 52.	0.7	1
52	Cardiovascular risk prediction—Are we missing something?. <i>European Journal of Heart Failure</i> , 2020, 22, 1291-1293.	2.9	1
53	Reassuring cardiac and non-cardiac outcomes for heart failure patients managed in a disease management programme during the COVID-19 pandemic. <i>IJC Heart and Vasculature</i> , 2022, 38, 100931.	0.6	1
54	FP551 REAL-TIME VOLUME ASSESSMENT TO GUIDE APPROPRIATE ULTRAFILTRATION IN HAEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i225-i225.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Reducing Heart Failure Risk in People With Diabetes: The STOP HF Midlands Project. <i>Journal of Cardiac Failure</i> , 2020, 26, 444-445.	0.7	0